Loading news...
We invest in secular growth and innovative businesses across all market capitalizations, with the bulk of the portfolio landing in the large-cap zone. We recently initiated a position in Axon Enterprise. We exited our successful investment in Exact Sciences Corporation after Abbott Laboratories announced it was acquiring the company for approximately $23 billion in cash.
The latest trading day saw Axon Enterprise (AXON) settling at $434.45, representing a -2.8% change from its previous close.
My methodology blends forward P/E ratios, company size, and default risk to rank Nasdaq 100 constituents by valuation. TSLA, INTC, AXON, PLTR, and CRWD are the most overvalued; PYPL, CTSH, ADBE, KHC, and PAYX are the most undervalued. Despite a $2.3trn market cap for the top 5 overvalued stocks, analysts expect higher earnings growth from the undervalued group.
Axon (AXON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Advisors Asset Management Inc. lowered its holdings in Axon Enterprise, Inc (NASDAQ: AXON) by 10.8% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,588 shares of the biotechnology company's stock after selling 2,132 shares during the period. Advisors Asset
Fears of disruption from AI programs have led to a sell-off in software stocks. Axon is down 50%, even though its business is anchored in hardware like the TASER.
SCOTTSDALE, Ariz., Feb. 10, 2026 /PRNewswire/ -- Axon (Nasdaq: AXON), the global public safety technology leader, today announced that it will report fourth quarter 2025 financial results after the market closes on Tuesday, February 24, 2026.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Penserra Capital Management LLC reduced its position in Axon Enterprise, Inc (NASDAQ: AXON) by 30.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,855 shares of the biotechnology company's stock after selling 2,164 shares during the period. Penserra Capital Management LLC's holdings in
Axon Enterprise (NASDAQ: AXON - Get Free Report) and Woodward (NASDAQ: WWD - Get Free Report) are both large-cap aerospace companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends. Analyst Recommendations This is a summary of recent
Axon (AXON) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Ten large-cap stocks posted steep weekly losses, driven by analyst downgrades, leadership headlines, and sector pressure across healthcare, tech, and precious metals.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
There was no company-specific news out on Axon last week. Instead, a broader sell-off in high-priced SaaS stocks took down Axon as well.
AustralianSuper Pty Ltd boosted its holdings in shares of Axon Enterprise, Inc (NASDAQ: AXON) by 2.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 82,779 shares of the biotechnology company's stock after acquiring an additional 1,806 shares during
Axon Enterprise (AXON) concluded the recent trading session at $549.86, signifying a -9.89% move from its prior day's close.
I reiterate a Strong Buy on AppLovin, driven by Axon Ads' accelerating network effects and AI-powered self-serve platform expansion. Axon's rapid onboarding of e-commerce advertisers, with 50% weekly spend growth, signals a powerful new growth engine beyond gaming. Prospecting campaigns and AI-generated creatives address key advertiser needs, boosting incremental sales and lowering barriers for smaller clients.
Axon stock fell 4% in 2025, marking its first losing year in a decade. The company seemed to be a victim of its own success as the stock got significantly more expensive over the last ten years.
Baillie Gifford and Co. decreased its holdings in shares of Axon Enterprise, Inc (NASDAQ: AXON) by 1.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 126,479 shares of the biotechnology company's stock after selling 1,771 shares during the period. Baillie
Exploring Baillie Gifford (Trades, Portfolio)'s Fourth Quarter 2025 Investment Adjustments Baillie Gifford (Trades, Portfolio) recently submitted the 13F filin